AVB Biotechnology was established in 2020 with the aim of developing treatment to end the Covid19 epidemic as soon as possible.
Serkan Tunç, the founder and Chairman of the Board of Directors of AVB Biotechnology, who is actually an economist, developed the "Signal Therapy Hypothesis" in March 2020 during the first period of the epidemic, and the Dr Biolyse® device, the implementer of this hypothesis, occurred.
In order to demonstrate the efficacy and safety of this new treatment, trials on incurable diseases are planned. Trials on bacteria and viruses have achieved successful results that could not have been achieved before, and diseases for which there is no valid treatment have been treated and continue to be treated.
With our young team focused on R&D trials and constantly developing innovative approaches, our story will continue until epidemics and infectious diseases are eradicated from animals and humans all over the world.